BBZA BB Biotech AG Ord

XETRA · DE · bbbiotech.ch
62.63USD57.10 EUR · XETRA-0.52%Mkt Cap: 3.45B USDP/E: —

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medica…

Institutional holders1 on file

Key Statistics

Company
Market Cap3.45B USD
Enterprise Value-160.78M USD
Revenue (TTM)1.31B USD
Gross Profit1.31B USD
Net Income (TTM)686.03M USD
Revenue/Share23.77 USD
Last Price62.63 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees10
CountryDE
Sector—
Industry—
ISINCH0038389992
Valuation
P/E (Trailing)—
P/E (Forward)26.11
PEG—
EV/EBITDA—
EV/Revenue-0.12
P/S2.85
P/B0.89
EPS (TTM)-10.11 USD
EPS (Forward)2.60 USD
52W Range
48.9277% of range66.69
52W High66.69 USD
52W Low48.92 USD
Profitability
Gross Margin100.00%
Oper. Margin96.19%
EBITDA Margin0.00%
Profit Margin98.49%
ROE20.81%
ROA20.75%
ROIC—
ROCE—
Growth
Revenue Growth-60.80%
Earnings Growth-61.20%
Cash Flow & Leverage
Operating CF232.46M USD
CapEx (TTM)—
FCF Margin63.08%
FCF Yield23.94%
Net Debt-3.91B USD
Net Debt/EBITDA—
Net Debt/FCF-4.73
Balance Sheet
Debt/Equity—
Current Ratio86.52
Quick Ratio86.51
Book Value/Sh75.74 USD
Cash/Share70.91 USD
Dividends
Fwd Div Rate—
Trail. Div Rate2.47 USD
Div. Yield—
5Y Avg Yield5.47%
Payout Ratio11.50%
Ex-Div DateMar 23, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)68.00 USD
Upside (mean)+8.6%
Target Range68.00 USD – 68.00 USD
# Analysts1
Ownership
Shares Out.55.15M
Float—
Insiders0.08%
Institutions20.71%
Technical
SMA 5036.63 (+71.0%)
SMA 20036.63 (+71.0%)
Beta0.68
S&P 52W Chg12.00%
Avg Vol (30d)5.87K
Avg Vol (10d)0
Technical Indicators
RSI (14)53.9
MACD0.9537
MACD Signal0.9804
MACD Hist.-0.0267
BB Upper66.32 USD
BB Middle62.08 USD
BB Lower57.84 USD
BB Width13.66%
ATR (14)1.362 USD
Vol Ratio (20d)1.12x

About BB Biotech AG Ord (ETR: BBZA)

›

BB Biotech AG Ord (ETR: BBZA) is listed on Xetra (Frankfurt), where its shares trade in EUR. It reports about 10 employees.

The shares were at 57.10 EUR on 19 November 2026, up 32.3% over 52 weeks. Its 52-week range is 44.60 EUR to 60.80 EUR: the price is 6.1% below the high and 28.0% above the low.

Its market capitalisation is 3.15B EUR.

BB Biotech AG Ord reports return on equity of 20.8%, an operating margin of 96.2% and revenue down 60.8% year over year.

It holds more cash than debt, a net cash position of 3.30B CHF. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 62.00 EUR is 8.6% above the current price. The next earnings report is expected on 19 February 2027.